

Pond Technologies

TSX.V: POND OTCQB: PNDHF

Corporate Presentation

July 2021

“Driving the future of an algae based bio-economy”

ADVISORY

This presentation contains forward-looking statements and information (collectively referred to as "forward-looking information") within the meaning of applicable securities laws about Pond's projections, targets and estimates based on certain assumptions disclosed in this advisory and in our publicly available documents available on SEDAR (sedar.com). Although Pond believes that the expectations represented by such forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information as actual results may differ materially from those expressed or implied. Pond undertakes no obligation to update or revise any forward-looking information except as required by law.

Forward-looking information in this presentation is identified by words such as "intended", "potentially", "anticipated", "planned" and "target" and includes: statements about the design, plans, timing, revenue and output capacity of Pond's plants; the harvest rate, land, capex and production using Pond's algae harvesting system.

Developing forward-looking information involves reliance on certain key expectations and assumptions made by Pond and consideration of certain risks and uncertainties, some of which are specific to Pond and others that apply to the industry generally. The assumptions on which the forward-looking information in this presentation is based include: the receipt of anticipated funding; the receipt of regulatory and partner approvals; the ability of Pond to raise capital; the ability of Pond to achieve commercial scaling; the increased demand for its products and the completion of plants as designed, scheduled and budgeted. Specifically, the underlying assumptions for output capacity for Pond projects as disclosed herein, and continuous commercial algae growth operations for 330 days/year.

Additional information about risks, assumptions and uncertainties and other factors that could cause Pond's actual results to differ materially from those expressed or implied herein is contained under the "Risk Factors" section of Pond's MD&A for the period ended March 31, 2021, available on Pond's website and on SEDAR (sedar.com).

TABLE OF CONTENTS



1. Company Overview & Technology
2. Pond Naturals
3. Pond Carbon
4. Pond Biotech
5. Company Ownership & Comps
6. Leadership

COMPANY OVERVIEW & TECHNOLOGY

POND: OVERVIEW



Pond Technologies (TSX.V: POND, OTCQB: PNDHF) is a Canadian technology company that has developed a proprietary algae growth platform to transform CO₂ into valuable products

Pond enables industry to monetize their waste emissions and reduce their carbon footprint

Pond enables Nutraceutical companies to reliably and sustainably produce high quality contaminant-free products for human consumption

Pond enables Diagnostic and Therapeutics companies to produce complex proteins at higher quality and lower cost than current alternatives

PONDTECH TECHNOLOGY PLATFORM



Pond harnesses CO₂ emissions to fuel the production of algae. Pond's state of the art photobioreactors apply advanced photosynthesis in a highly controlled environment under tightly monitored conditions to produce protein-rich algae, a saleable asset to manufacturers of pharmaceuticals, animal feeds, and more.

Pond Algae Platform



CONTROLLED GROWTH OUTPERFORMS



Pond boosts the productivity of micro-algae through growth optimization technology.



Current Competitors' Outdoor Methods:

- Algae grows in top few inches only
- Large area required
- Large cooling and water requirements
- Climate dependent
- Contamination vulnerable
- Daylight hours only



Pond's Growth Platform:

- Controls total growth environment including light, gases and temperature in enclosed photo-bioreactors
- Increased yield
- Less contamination
- Operates 24/7 year-round
- A fraction of land required
- Uses less water than outdoor farms



MARKET APPLICATIONS



- The market for algae is a multibillion-dollar industry, and our patented technology can capture various market segments
- Pond's proprietary technology is protected by an extensive IP portfolio including 19 active patents in the key markets like the United States, Europe, Taiwan, China, and the Middle East.

NUTRACEUTICALS

Target Market: >\$10 billion
CAGR: 10% – 20%
Price per tonne: \$10,000 - \$450,000




FISH & ANIMAL FEEDS

Target Market: >\$20 billion
CAGR: 10%
Price per tonne: \$1,500 - \$3,000



BIOTECH

Target Market: >\$600 billion
CAGR: 12%
Price per Kilogram: >\$10,000,000



Bio-Remediation

Target Market: >\$100 billion
CAGR: 9%



EXTENSIVE INTELLECTUAL PROPERTY



Pond has a global patent portfolio covering its proprietary algae production platform.

19

Active US Patents

9 US patents in process, with over 3x more patents filed internationally

Patents granted to date include:

- 4 US (+ 5 in progress)
- 12 Europe (2 patents in 6 countries)
 - ▶ UK, Germany, France, Switzerland, Italy, Netherlands
- 1 Taiwan
- 1 China
- 1 Middle East (6 GCC countries)
 - ▶ Saudi Arabia, UAE, Kuwait, Oman, Qatar, Bahrain



Algae Platform Protection

Modulation patents protect flow of stack gas – crucial for industrial algae growth

Dilution patents protect mixing of stack gas

Adaptive control system that predicts optimum harvest rates based on growth



Patents Pending


24 International Patents in process globally, also protect IP portfolio in Canada, Australia, India

Potential for 5+ additional equipment-related US patents on new technologies

Equipment related patents to cover new equipment

Advanced process patents

DIVISIONS



POND NATURALS

POND NATURALS: OVERVIEW

Pond Naturals comprises a distribution channel for natural products and a manufacturing operation to develop algae-based products to distribute through that distribution channel.

- Pond distributes a variety of natural products ranging from bulk ingredients to white-label consumer products and branded consumer products
- Pond's B.C. facility grows and sells astaxanthin under its own brand "**Regenurex**" as well through white label arrangements.
 - The **proprietary wet extraction process** gently extracts astaxanthin oleoresin without the use of dehydration or harsh chemicals.
- Pond is developing additional algal products such as phycocyanin
 - Phycocyanin is the only FDA approved blue food colouring. Pond is developing extraction methods to offer industrial users safe domestic supplies.
- As a "Made in Canada" product, it can be sold as bulk wholesale, white labelled, or into our branded product (Regenurex) and provides consumers security of supply compared to overseas producers,



Existing commercial production and extraction of astaxanthin at Pond's British Columbia facility

STRATEGIC GOAL:

To make Pond Naturals the premier solution for domestic production and distribution of a variety of highest quality bulk and consumer natural products.

BUSINESS FOCUS:

- White label and Regenurex branded consumer products
- Development of value-added formulations
- Trusted high quality ingredients including proprietary extraction methods that increase confidence
- Increasing number of algae extracted products
- Domestic source to reduce supply chain risk for buyers and certainty of quality

POND NATURALS: DRIVE SALES

Increase sale through increased branded and white label sales.

- New white label partners for existing algal products including astaxanthin.
- Increased distribution of bulk products sales.
- Increased branded sales.

Develop new value-added products and new ingredients.

- Develop new astaxanthin products for both consumers and producers.
- Develop a proprietary high yield phycocyanin production and extraction system.

POND NATURALS: INCREASED CAPACITY

Improve manufacturing capacity to match improved sales.

- Increase manufacturing capacity to match increased demand for astaxanthin driven by increased sales and value-added products.
- Build new phycocyanin growth and extraction capacity to meet producer demand for domestic source.
- Build other algae production to support increased sales of other algae products including spirulina.

POND NATURALS: TARGETED IMPROVEMENTS

- 
- Improve Sales & Marketing Efforts
 - White label
 - Branded
 - Expand Distribution Channels

2021

- 
- Increase production capacity
 - Increase separation capacity

2022

POND CARBON

POND CARBON: OVERVIEW



Pond Carbon develops carbon capture projects, providing operational resources from initial consulting to project completion.

- Lab/engineering resources to develop commercial processes for CO₂ abatement.
- Develops algae bioreactor technology for licensing and royalty revenue, in both R&D demonstration systems and full commercial systems.
- Custom build and implement each carbon-reducing project to customers' needs, transforming carbon into a valuable product.
- Commercializes specific algae-based carbon capture products.

STRATEGIC GOAL:

To make Pond Technologies the global leading solution for commercial scale deployment of algae photobioreactors that can reduce carbon emissions and produce algae in the food, feed and biofertilizer market.

BUSINESS FOCUS:

- Supporting the deployment of algae systems on customers' sites, including proprietary bioreactors and supporting systems
- Provide service and support to ensure ongoing royalties
- Development of specific market opportunities for algae-based products

POND CARBON: IDEAL CUSTOMERS



Has a **carbon footprint, stack gas** and a **use for algae-based products**.

Ideal projects:

- Animal feed company, with manufacturing assets and can use algae as a premium animal feed ingredient.
- Natural resource operation with carbon emissions and a need for land reclamation and remediation.
- Human nutraceutical company with manufacturing assets, where algae based functional foods and supplements are in demand.

POND CARBON: PROJECTS IN DEVELOPMENT



Animal Feed Vertical:

- Major global animal feed producer and distributor.
- Seeking to commercialize premium algae-based animal and aquaculture feed additives.
- Engineering, equipment purchase, upfront license and ongoing royalty.

Natural Resource Vertical:

- Major global oil and gas company.
- Seeking carbon abatement and bio-remediation.
- Genetic engineering (Pond Biotech), engineering, equipment purchase, upfront license and ongoing royalty.

Precision Agriculture Vertical:

- Specialty agriculture company.
- Seeking to diversify into algae-based food ingredient and nutraceuticals.
- Engineering, equipment purchase, upfront license and ongoing royalty.

POND BIOTECH

Pond Biotech represents an immediate and long-term value creation opportunity by using Pond Tech's algae-based system to develop and manufacture valuable algae strains for use in human and animal therapeutic solutions.

- Successfully grew genetically modified algae that express COVID-19 Antigens for diagnostic use under contract to major Canadian industrial company.
- Developing other recombinant proteins expressed in algae.
- Developing internal genetic engineering capability to better serve Pond and outside customers.
- Algae are a cost-effective solution to grow many recombinant proteins compared to mammalian cell lines.



STRATEGIC GOAL:

To make Pond Biotech the leading biological solution for the low-cost manufacture of diagnostics, vaccines, and therapeutics through the use of algal production systems. The combination of higher productivity and simpler growing conditions are expected to result in a cost advantage in production.

BUSINESS FOCUS:

The initial business focus is on the development and growth of genetically modified algae strains that can express valuable proteins for use in diagnostic and therapeutic applications. The division was created to become a CMO for bio-tech and pharmaceutical companies looking to grow specific proteins at scale.

Problem for Bio-Pharma: Grow Quality Proteins at scale for Diagnostics and Therapeutics

- Current production of complex proteins in mammalian cell lines is difficult and low productivity.
- Difficult to scale with consistent quality.
- Requires complex bioreactors and control systems to manage the culture environment.
- The current system for cultivating these proteins is expensive compared to Algae.

Pond's Solution for Bio-Pharma: Genetically Modified Algae Strains

- ✓ Controlled growth environment for genetically modified algae that can express proteins for diagnostics and therapeutics.
- ✓ Consistent quality due to contained growth system.
- ✓ Proven scalability.
- ✓ Proper protein folding.
- ✓ Less expensive.

Algae



Higher yield manufacturing



Simple growing conditions



Reduced manufacturing footprint



Robust cultures tolerate variation of temperature and growing media

Mammalian Cell Culture



Low yield manufacturing



Complex growing conditions



Large manufacturing footprint



Delicate cultures requiring precise control of temperature and growing media

Immediate Opportunity

Diagnostic reagents

- Cost advantage in reagents
- No requirement to develop testing platform(s)

Future Opportunities

Human therapeutics

- Provides “proof of concept” to manufacturing opportunity
- Potential to develop therapeutics (novel and biosimilar)

Contract manufacturing

- Provide manufacturing capabilities to pharmaceutical companies looking for cost improvements

COMPANY OWNERSHIP & COMPS

EQUITY TABLE



Company insiders own approximately 19% of the shares outstanding, on a fully diluted basis

	Shares (millions)
Common Shares Issued (as of 7/12/21):	42,971,268
Reserved for Regenurex Acquisition	4,616,960
Common Shares Issued and Reserved	47,588,228
DSU	456,317
Warrants	
\$0.45 / share Exp. March 2023	10,437,696
\$0.25 / share Exp. June 2022	1,095,400
\$1.00 / share. Exp. December 2021	2,742,504
Employee Stock Options:	4,005,000
Convertible Note, \$1/share Matures November 2021	2,000,000
Fully Diluted	68,325,145

INDUSTRY COMPARABLES



Questor Technology (QST.V)

Market Cap: \$54M

Questor Technology Inc., an environmental clean technology company, designs, manufactures, and services waste gas combustion systems in Canada and the United States.

Fuel Tech (FTEK.Q)

Market Cap: \$69M

Company operates through two segments, Air Pollution Control Technology and FUEL CHEM Technology. The Air Pollution Control Technology segment offers technologies to reduce nitrogen oxide (NOx) emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources by low and ultra-low NOx burners; over-fire air systems.

Pacific Green Technologies (OTCQB:PGTK)

Market Cap: \$88M

acquires, develops, and markets emission control technologies in North America, Europe, and Asia. The company offers ENVI-Clean, a system that removes sulphur dioxides, particulate matters, greenhouse gases,

LiqTech International (LIQT.Q)

Market Cap: \$155M

Clean technology company that designs, develops, produces, markets, and sells automated filtering systems, and ceramic silicon carbide liquid applications and diesel particulate air filters

Advanced Emissions Solutions (ADES.Q)

Market Cap: \$133M

The company's products are used in removal of heavy metal pollutants; treatment of drinking and waste waters; industrial acid gas and odor removal; automotive gasoline emission control; soil and ground water remediation; and food and beverage process and product purifications.

Greenlane Renewables (GRN.TO)

Market Cap: \$216M

The company's systems remove impurities and separate carbon dioxide from biomethane in the raw biogas created from anaerobic decomposition of organic waste at landfills, wastewater treatment plants, and farms and for injection food waste facilities into the natural gas grid or for direct use as vehicle fuel.

Bion Enviromental (OTCMKTS: BNET)

Market Cap: \$50M

The company's technology remediates environmental problems and improve operational/resource efficiencies through recovering co-products from the CAFOs' waste stream, including renewable energy and water, and nutrients comprising ammonia nitrogen and phosphorus.

Midwest Energy Emissions (OTCMKTS: MEEC)

Market Cap: \$84M

Operates as an environmental services and technology company. It focuses on the delivery of mercury capture technologies to coal-fired power plants

LEADERSHIP

MANAGEMENT TEAM



Grant Smith

Chief Executive Officer

Executive with 20+ years experience in the global health supplements and ingredients space

Co-Founder & partner at RFI Canada, the distributor for ingredients to well-known consumer brands across North America



Thomas Masney

Chief Financial Officer

Worked with Goldman Sachs & GE in venture capital, mergers & acquisitions, and for both Ernst & Young and Price Waterhouse in audit and corporate recovery.

Thomas brings with him a strong understanding of the mining, construction, manufacturing, technology, and e-commerce industries.



Peter Howard

Vice President, Pond Carbon

Senior business development and cleantech executive. Climate change and sustainability consulting experience with PwC and Zerofootprint, developing multi-million dollar business lines.

Senior policy advisor to Canadian governments on climate change policy.



Nigel Degruyther

Vice President, Pond Biotech

Nigel has broad and varied experience in the life sciences field with an emphasis on assessing, analyzing, and presenting commercial opportunities.

Nigel also gained global operating company experience at Guidant, a multinational developer of medical devices, where he worked directly with country heads and senior management of various functions including sales, marketing, and manufacturing.

BOARD OF DIRECTORS



Robert McLeese, *Chairman*

Mr. McLeese, is the Founder and President of Access Capital Corp. “Access” is a Toronto based Financial Advisory firm specializing in the independent power industry for over 30 years. Rob currently serves on the Board of Export Development Canada and is the Chair of its Audit Committee. He is also Chair of Pond Technologies Inc., an Ontario technology company with a highly innovative CO₂ capture technology and algae growing expertise.



Grant Smith, *Director*

Executive with 20+ years experience in the global health supplements and ingredients space. Co-Founder & partner at RFI Canada, the distributor for ingredients to well-known consumer brands across North America.



Jacob Gamble, *Director*

Jacob Gamble has more than 20 years of combined global experience in management consulting, investment banking, growth initiatives, and corporate communications.



John M. Farah Jr., PhD, *Director*

John M. Farah Jr, PhD has over 30 years of experience in health care and the biopharmaceutical industry. He is currently a senior clinical consultant with Veradigm, an Allscripts business, leveraging real-world data and real-world evidence for insights into challenges and opportunities in care of patients with chronic health conditions.



J. William Asseltine, *Director*

J. William Asseltine has been employed at St Marys Cement for over forty years and has held various positions within the company, including Vice President of Logistics, Sustainability and Cement Sales in Canada. Mr. Asseltine graduated from the University of Toronto and is a Professional Engineer in the Province of Ontario. He resides in Oakville.

CONTACT INFORMATION



Pond Technologies Holdings Inc. Head Office

250 Shields Court, Unit 8

Markham, Ontario

L3R 9W7

Tel. +1 (416) 287-3835

Cole Stevens

Corporate Development

c.stevens@pondtech.com

